Bristol-Myers Squibb reports Q3 2024 earnings and outlines future strategies

Bristol-Myers Squibb reported its Q3 2024 earnings today, highlighting key financial results and developments. The company is focusing on its ongoing drug development and commercialization efforts, with leadership participating in the call to discuss these updates. CEO Chris Boerner and CFO David Elkins provided insights into the company's performance and future strategies. They emphasized the importance of their pipeline and market positioning in the competitive pharmaceutical landscape. The earnings call included participation from various financial analysts, indicating strong interest in Bristol-Myers Squibb's performance and future prospects. The company aims to maintain transparency and engagement with investors.